Literature DB >> 1356443

Apolipoprotein E1 Lys-146----Glu with type III hyperlipoproteinemia.

K Moriyama1, J Sasaki, A Matsunaga, F Arakawa, Y Takada, K Araki, S Kaneko, K Arakawa.   

Abstract

During the screening of samples obtained from 5 individuals with type III hyperlipidemia, we identified a variant of apolipoprotein (apo) E which exhibited a discrepancy in apo E phenotype showing the E3/E1 isoform on isoelectric focusing (IEF) analysis and E3/E3 on gene analysis. Sequence analysis of the DNA of the proband that was amplified by PCR and subcloned, revealed a single substitution of one lysine (AAG) for one glutamic acid (GAG) at position 146, thereby adding two negatively charged units to apo E3. This defect had been described only for apo E1 to date (Mann et al. (1989) Clin. Res. 37, 520A (abstract)). In this case, PCR-mediated site-directed mutagenesis was used to identify the structural alterations forming the abnormal E1 genotype in the proband's family. Purified apo E1 Lys-146----Glu showed less than 10% of binding activity to apo B, E receptor on human skin fibroblasts compared with apo E3. This substitution demonstrates that Lys-146 is essential for the binding of apo E to the receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1356443     DOI: 10.1016/0005-2760(92)90257-v

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  7 in total

1.  The fourth apolipoprotein E haplotype found in the Yoruba of Ibadan.

Authors:  Jill R Murrell; Brandon M Price; Olusegun Baiyewu; Oye Gureje; Mark Deeg; Hugh Hendrie; Adesola Ogunniyi; Kathleen Hall
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-06-05       Impact factor: 3.568

Review 2.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

3.  Associations of APOE Gene Variants rs429358 and rs7412 with Parameters of the Blood Lipid Profile and the Risk of Myocardial Infarction and Death in a White Population of Western Siberia.

Authors:  Sergey Semaev; Elena Shakhtshneider; Liliya Shcherbakova; Dinara Ivanoshchuk; Pavel Orlov; Sophia Malyutina; Valery Gafarov; Yuliya Ragino; Mikhail Voevoda
Journal:  Curr Issues Mol Biol       Date:  2022-04-13       Impact factor: 2.976

4.  Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.

Authors:  P de Knijff; A M van den Maagdenberg; D I Boomsma; A F Stalenhoef; A H Smelt; J J Kastelein; A D Marais; R R Frants; L M Havekes
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

5.  Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146-->Glu).

Authors:  W A Mann; P Lohse; R E Gregg; R Ronan; J M Hoeg; L A Zech; H B Brewer
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

6.  Biophysical analysis of apolipoprotein E3 variants linked with development of type III hyperlipoproteinemia.

Authors:  Dimitra Georgiadou; Angeliki Chroni; Alexander Vezeridis; Vassilis I Zannis; Efstratios Stratikos
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

Review 7.  Establishing the relationship between familial dysbetalipoproteinemia and genetic variants in the APOE gene.

Authors:  Britt E Heidemann; Charlotte Koopal; Alexis Baass; Joep C Defesche; Linda Zuurbier; Monique T Mulder; Jeanine E Roeters van Lennep; Niels P Riksen; Christopher Boot; A David Marais; Frank L J Visseren
Journal:  Clin Genet       Date:  2022-08-22       Impact factor: 4.296

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.